By Sai Ishwarbharath B and Rishika Sadam
BENGALURU/HYDERABAD, July 2 (Reuters) – – Medical device maker Zimmer Biomet plans to hire 500 employees over the next three years for its newly opened technology centre in Bengaluru, a senior executive said, as the U.S.-listed company expands its presence in India.
The hires will span software engineering, product design, research and development, and functions such as quality, regulatory and finance, Jehanzeb Noor, chief strategy, business development, innovation and transformation officer, said on Wednesday.
About two-thirds of the hires will be in technology roles, with the remainder in support functions, Noor said, adding that the company was not constrained on hiring and could significantly expand headcount to thousands in the future.
The expansion comes as India strengthens its position as a hub for global capability centres. Healthcare companies including Novo Nordisk, AstraZeneca and Eli Lilly use their India centres for research and development, clinical data analysis, regulatory work and technology.
GCC consultant ANSR estimates revenue from India’s global capability centres will rise 12% to $84 billion in the financial year ending 2026, the firm told Reuters.
Zimmer Biomet, whose key markets include the United States, Europe and Japan, makes orthopedic implants for knee, hip and shoulder replacements, as well as surgical and robotic devices for musculoskeletal conditions.
“We want to make sure that we have a centre that has all the appropriate functions running together so we can drive innovation and bring that back to our surgeons, care teams and patients,” Chief Information and Technology Officer Shaun Braun said.
The company said the centre would focus heavily on artificial intelligence, with applications spanning robotics, surgical planning and research and development, as it looks to expand the use of AI in its products and speed up development.
(Reporting by Sai Ishwarbharath B in Bengaluru and Rishika Sadam in Hyderabad; Editing by Nivedita Bhattacharjee)
Comments